Latest News
Positive near-term catalysts for Rio Tinto limited, says BoA Merrill Lynch
Bank of America Merrill Lynch cut its stance on miner Rio Tinto to 'underperform' from 'neutral' on Thursday, slashing the price target to 4,150p from 4,770p as it noted limited positive catalysts in the near term.
Chicago PMI beats expectations in February
Economic activity in the Chicago area improved much more than expected in February amid a surge in new orders, according to figures released on Thursday.
US initial jobless claims rise more than expected
The number of Americans filing for unemployment benefits rose more than expected last week, according to figures from the Labor Department.
US Q4 GDP beats forecasts despite government shutdown
The US economic expansion ebbed at the tail-end of 2018, as the pace of inventory accumulation and spending by households and the federal government slowed while state and local governments retrenched, albeit by less than had been anticipated.
Immotion Group signs distribution deal for Middle East and North Africa
Virtual reality (VR) attraction company Immotion Group has appointed Dubai-based Warehouse of Games as its exclusive distribution partner for the Middle East and North Africa (MENA) territories, it announced on Thursday.
US consumer demand leads to more fragrant Byotrol variant
Specialist anti-microbial technology company Byotrol has completed the product registration process in the United States for two new, improved versions of its 24-hour germ-kill surface sanitiser, 'Byotrol24’, it announced on Thursday.
Amryt gets approval to extend EASE trial to infants and children
Orphan drug company Amryt Pharma updated the market on its phase 3 ‘EASE’ trial for AP101 as a potential treatment for epidermolysis bullosa (EB) on Thursday, reporting that following an assessment by the trial's independent data monitoring committee, it could now enrol infants and children with EB between the ages of 21 days to four years in the trial.
Sareum flags potentially significant findings for SRA737
Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.
GoCompare profit and revenue rise, plans £10m investment in weflip
Price comparison website GoCompare posted a rise in full-year operating profit and revenue on Thursday as it announced a £10m investment in its weflip service.
Asia report: Most markets falter on failure of Trump-Kim talks
Most markets in Asia were in the red at the close on Thursday, after the summit between US president Donald Trump and North Korea leader Kim Jong-un was wound up early, with no agreement being reached between the two nations.
Conroy Gold narrows losses, project development continues
Ireland-based resource company Conroy Gold and Natural Resources narrowed losses in the first half of its trading year.
Applied Graphene soars on 'fivefold' technology improvement
Applied Graphene Materials' (AGM) shares shot up on Thursday after the business announced that its breakthrough graphene technology has delivered "outstanding" anti-corrosion performance enhancement results that has led the business to be nominated for a key industry award.
UK miners looking overbought, telecoms very oversold - Morgan Stanley
The mining sector is starting to look overbought, according to Morgan Stanley, following a bumper quarter.
Foxtons swings to a loss as London sales market struggles
Foxtons said on Thursday that it swung to a loss in 2018 as it warned that the London sales market is in "a prolonged downturn".
Itaconix leaps on second Nouryon supply agreement
Itaconix's shares soared on Thursday after the business signed a supply agreement for its bio-based polymers with chemical firm Nouryon.
Genus swings to loss after being hit by pension charges
Genus on Thursday confirmed that it swung to an interim loss as revenue remained flat as the livestock genetics specialist was hit by non-cash accounting charges and the effects of the rapid spread of African Swine Fever in China.
Europe midday: Stocks mired in slight losses amid geopolitical headlines
Stocks are holding slightly lower come midday as investors digest news that the second round of nuclear talks between the US and North Korea has ended without a deal, reportedly after Pyongyang called on Washington to lift all its sanctions, and a weaker reading on China's manufacturing sector.
Telford cuts £10m off full-year profit guidance
Residential property developer Telford Homes slashed its full-year profit guidance by a minimum of £10m on Thursday, sending its shares south.
Immigration from EU into the UK at 10-year low
Long-term immigration to the UK has fallen to its lowest level since 2014, government data showed on Thursday, with migration from the European Union hitting a ten-year low.
Greencoat puts in decent performance despite lack of wind
Greencoat UK Wind said it performed in line with its expectations in its results for 2018 on Thursday, with cash generation on budget.